Abstract DP221: Post-Hoc Analysis of RESCUE in Participants Enrolled <12h Since Symptom Onset Substantiates ITT Population Results

Background: Despite transformational advances in reperfusion therapies, acute ischemic (AIS) stroke remains a leading cause of death and long-term disability, underscoring a critical unmet need for adjunctive cerebroprotective strategies. RNS60, oxygen supersaturated in saline with a patented technology, was tested as a drug candidate for such an adjunctive therapy. Methods: RESCUE, a proof-of-concept phase 2 trial, showed that RNS60 treatment for 48h starting during endovascular thrombectomy (EVT) in 82 participants with large vessel occlusion enrolled within 24h since symptom onset was safe, reduced post reperfusion infarct growth by 47% at 48h (nominal p